EP0497275A3 - Generation of cd4+ helper t cells with interleukin 2 and interleukin 4 from l-phenylalanine methyl ester treated human peripheral blood cells - Google Patents

Generation of cd4+ helper t cells with interleukin 2 and interleukin 4 from l-phenylalanine methyl ester treated human peripheral blood cells Download PDF

Info

Publication number
EP0497275A3
EP0497275A3 EP19920101351 EP92101351A EP0497275A3 EP 0497275 A3 EP0497275 A3 EP 0497275A3 EP 19920101351 EP19920101351 EP 19920101351 EP 92101351 A EP92101351 A EP 92101351A EP 0497275 A3 EP0497275 A3 EP 0497275A3
Authority
EP
European Patent Office
Prior art keywords
interleukin
cells
helper
generation
methyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920101351
Other languages
English (en)
Other versions
EP0497275A2 (de
Inventor
Kam H. Leung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Publication of EP0497275A2 publication Critical patent/EP0497275A2/de
Publication of EP0497275A3 publication Critical patent/EP0497275A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19920101351 1991-01-31 1992-01-28 Generation of cd4+ helper t cells with interleukin 2 and interleukin 4 from l-phenylalanine methyl ester treated human peripheral blood cells Withdrawn EP0497275A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/648,672 US5374549A (en) 1991-01-31 1991-01-31 Process of enriching adherent CD4+ T cells from monocyte depleted peripheral blood mononuclear cells with interleukin 2 and interleukin 4
US648672 2003-08-26

Publications (2)

Publication Number Publication Date
EP0497275A2 EP0497275A2 (de) 1992-08-05
EP0497275A3 true EP0497275A3 (en) 1993-02-10

Family

ID=24601742

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920101351 Withdrawn EP0497275A3 (en) 1991-01-31 1992-01-28 Generation of cd4+ helper t cells with interleukin 2 and interleukin 4 from l-phenylalanine methyl ester treated human peripheral blood cells

Country Status (4)

Country Link
US (1) US5374549A (de)
EP (1) EP0497275A3 (de)
JP (1) JPH04325087A (de)
CA (1) CA2060270A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2729570A1 (fr) 1995-01-24 1996-07-26 Idm Immuno Designed Molecules Procede de preparation de macrophages actives, trousses et compositions pour la mise en oeuvre de ce procede
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
AU3066599A (en) 1998-03-03 1999-10-18 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
US20010051928A1 (en) * 2000-04-21 2001-12-13 Moshe Brody Protection of software by personalization, and an arrangement, method, and system therefor
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
JP2005514054A (ja) * 2001-12-21 2005-05-19 ユニバーシティ・オブ・サザン・カリフォルニア プロフェッショナルおよびサイトカイン産生制御ｔ細胞の誘導のための方法
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
WO2006049439A1 (en) * 2004-11-03 2006-05-11 Dinona Inc. Method of producing xenogenic cd4 t-cell and animal model producing xenogenic cd4 t-cell
KR100666607B1 (ko) * 2004-11-03 2007-01-09 재단법인서울대학교산학협력재단 이종의 ｃｄ４ ｔ-세포 생산방법 및 이종의 ｃｄ４ｔ-세포를 생산하는 동물모델
KR100735081B1 (ko) * 2005-04-21 2007-07-06 고려대학교 산학협력단 Ｃｄ4 ｔ 세포 활성화 방법
KR100735083B1 (ko) * 2005-04-21 2007-07-06 고려대학교 산학협력단 Ｃｄ8 ｔ 세포 활성화 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849329A (en) * 1986-05-30 1989-07-18 E. I. Du Pont De Nemours And Company Process for preparing lymphokine activated killer cells
WO1990010059A1 (en) * 1989-02-21 1990-09-07 Terumo Corporation A process for the generation of proliferating cd4 lymphocytes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108760A (en) * 1989-07-21 1992-04-28 Terumo Corporation Enhances lak cell activation by treatment of human peripheral blood mononuclear cells with amino acid amides
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849329A (en) * 1986-05-30 1989-07-18 E. I. Du Pont De Nemours And Company Process for preparing lymphokine activated killer cells
WO1990010059A1 (en) * 1989-02-21 1990-09-07 Terumo Corporation A process for the generation of proliferating cd4 lymphocytes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF IMMUNOLOGY. vol. 139, no. 4, 15 August 1987, BALTIMORE US pages 1142 - 1147 HERGEN SPITS ET AL 'Recombinant interleukin 4 promotes the growth of human T cells' *

Also Published As

Publication number Publication date
EP0497275A2 (de) 1992-08-05
US5374549A (en) 1994-12-20
CA2060270A1 (en) 1992-08-01
JPH04325087A (ja) 1992-11-13

Similar Documents

Publication Publication Date Title
ZA899176B (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma and pharmaceutical compositions useful in such treatment
AU4030089A (en) Artificial heart structure and methods of use
AU3212689A (en) Medical material permitting cells to enter thereinto and artificial skin
HU9302049D0 (en) Trans-splitting ribosimes and elimination of cells using them
EP0871707A4 (de) Manipulation von pflanzlichen zell-und gewebekulturen
PL312718A1 (en) Competitors and opponents of human interleukine-10
EP0557388A4 (en) Diagnosis and treatment of multiple sclerosis
AU2975692A (en) Expression vectors and their use in the preparation of HIV-resistant human cells for therapeutic applications
HUP9800829A3 (en) Collagen-based methods and formulations for the treatment of immune system-mediated diseases
AU3212589A (en) Medical material permitting cells to enter thereinto and artificial skin
AU5466794A (en) Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis
EP0269017A3 (en) Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein
AU7577091A (en) Process for the artificial stimulation of cells and cyte culture device
ZA925514B (en) Expression of enzymatically active recombinant human actylcholinesterase and use thereof
PL268520A1 (en) Specific fighting the growth of microorganisms and plant diseases
GB9602721D0 (en) Biologically active ureido derivatives useful in the treatment of multiple sclerosis
GB9307948D0 (en) Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease
CS4488A1 (en) Diagram of characteristics' group linearization and scaling
ZA89629B (en) Use of cyclophilin as an anti-inflammatory and immunomodulatory agent
GB2270324B (en) Treatment of y"-hardening nickel-based alloys
EP0598269A3 (en) Apparatus for the culture of living cells and tissues.
AU7578091A (en) Treatment of cachexia with interleukin 2
AU3651689A (en) Cloning and expression of human tissue factor
ZA929129B (en) Expression vectors and their use in the preparation of HIV-resistant human cells for therapeutic applications
IL103865A0 (en) Expression vectors and their use in the preparation of hiv-resistant human cells for therapeutic applications

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): CH DE FR GB IT LI NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): CH DE FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19930224

17Q First examination report despatched

Effective date: 19951117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960328